초록 ▼

This application relates to a pharmaceutical composition for the prevention and treatment of skin conditions in a patient having a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin, a primary antioxidant component in an amount sufficie

This application relates to a pharmaceutical composition for the prevention and treatment of skin conditions in a patient having a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin, a primary antioxidant component in an amount sufficient to substantially inhibit the formation of collagenase and elastase, at least one amino acid component in an amount sufficient to assist in the thickening of the skin, and at least one transition metal component in an amount effective to bind collagen and elastic fibers and rebuild skin. In one preferred form, the composition further includes a catechin-based preparation, a glucosamine or a pharmaceutically acceptable salt or ester thereof, and a chondroitin or a pharmaceutically acceptable salt or ester thereof. In a more preferred form, the invention further includes a vitamin E source, a cysteine source, a vitamin B.sub.3 source, quercetin dihydrate, pyridoxal 5 phosphate-Co B.sub.6, a methionine source, and a vitamin A source. The invention further relates to a method for the prevention or treatment of skin conditions by administering the pharmaceutical composition in an amount therapeutically effective to modify the thickness of the skin to prevent or treat at least one skin condition.

대표청구항 ▼

[ What is claimed is:] [1.] An orally administered pharmaceutical composition for the prevention and treatment of skin conditions in a patient comprising the following components:a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin;a pr

[ What is claimed is:] [1.] An orally administered pharmaceutical composition for the prevention and treatment of skin conditions in a patient comprising the following components:a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin;a primary antioxidant component in an amount sufficient to substantially inhibit the activity of collagenase and elastase;at least one amino acid component in an amount sufficient to assist in the thickening of the skin;at least one transition metal component in an amount effective to bind collagen and elastic fibers and thicken skin; and a catechin-based component present in an amount sufficient to inhibit the presence of anti-collagen enzyme in the skin.